Trial Profile
A Randomised, Crossover study to evaluate interaction between Sitagliptin and ACE inhibitors (Ramipril, Valsartan and Amlodipine) and their effect on Hemodynamic and Metabolic Response in patients with Type 2 Diabetes and Hypertension
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Oct 2018
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary) ; Amlodipine; Aprepitant; Ramipril; Valsartan
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 15 Oct 2018 New trial record
- 09 Sep 2018 Results presented at the Hypertension Scientific Session 2018